Navigation Links
Breast Radiation After Lumpectomy Saves Lives: Study

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Oct. 19 (HealthDay News) -- Women with breast cancer who undergo radiation after a lumpectomy have significantly fewer recurrences and, consequently, greater odds of survival than women who forgo radiation, new research says.

The study also noted no long-term adverse effects from radiation after this breast-conserving surgery, as deaths from any cause were also reduced substantially.

"For the first time, this showed this important linkage between using radiation to avoid local recurrence and improving long-term survival," said Dr. Jay Harris, chairman of radiation oncology at Dana-Farber Cancer Institute and Brigham & Women's Hospital in Boston. "Up until 2005, the prevailing attitude in the U.S. was that radiation did not have an impact on improving long-term survival and was strictly to reduce local recurrence."

Giving radiotherapy after breast-conserving treatment is already common practice, said Dr. Shelly Hayes, a radiation oncologist with Fox Chase Cancer Center in Philadelphia. The point is to destroy any stray cells in the affected breast.

The findings echo the results of a landmark 2005 paper that involved fewer women and shorter follow-up. They should help erase any lingering doubts among skeptics, experts said.

"It is going to be very helpful to see updated results with lots more patients, lots more follow-up and this is very substantial improvement in long-term outcome," Harris said.

Here, the authors assessed data on almost 11,000 women in 17 randomized trials that compared radiation with no radiation after lumpectomy.

The authors took the unusual step of including both published and unpublished trials, making "the data very reliable," said Harris.

Overall, irradiating the affected breast halved recurrence rates and cut the mortality rate by one-sixth, the researchers said.

After 10 years, 19 percent of women who had undergone radiation had had a recurrence compared with almost twice as many -- 35 percent -- in the non-radiation group.

And 15 years after diagnosis, 25 percent of women with radiation were alive, vs. 21 percent in the control group. At that time, the absolute risk reduction in all-cause mortality was 3 percent, the study found.

The numbers varied according to age, grade of tumor, estrogen-receptor status, whether the patient had taken the estrogen-suppressing drug tamoxifen and how extensive the surgery had been.

"The magnitude of the benefit got smaller with more favorable factors, but there were benefits in every subgroup, which translated into benefit in terms of recurrence risk, which translated into overall survival," Hayes said.

"Across the board, no matter what those features were, women benefited from radiation," Hayes said.

For some time, doctors have wondered whether radiation was really necessary for all women, said study co-author Sarah Darby, professor of medical statistics at the University of Oxford in England.

"These findings will enable both doctors and patients to have a better idea of the benefit that is likely to be gained from radiotherapy on a patient-by-patient basis," she said.

More information

The U.S. National Cancer Institute has more on breast cancer treatments.

SOURCES: Sarah Darby, Ph.D., professor, medical statistics, University of Oxford, England; Shelly Hayes, M.D., radiation oncologist, Fox Chase Cancer Center, Philadelphia; Jay R. Harris, M.D., professor and chairman, radiation oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston; Oct. 20, 2011, The Lancet, online

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
Related Image:
Breast Radiation After Lumpectomy Saves Lives: Study
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology: